jDAPA-PD

Not Applicable

• Conditions: Chronic heart failure, chronic kidney disease; Chronic heart failure, chronic kidney disease, peritoneal dialysis

• Registration Number: JPRN-jRCT1031230624
• Lead Sponsor: Yamamoto Suguru

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-02-08
• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1) Patients who provide written consent based on their own free will to participate in this study.
2) Patients who are 18 years of age or older
3) Patients who are undergoing peritoneal dialysis for the treatment of end-stage kidney disease for more than 3 months
4) Patients whose peritoneal dialysis regimen is stable for at least 4 weeks
5) Patients who are diagnosed with chronic heart failure and receiving standard treatment

Exclusion Criteria

1) Patients who are participating in other clinical studies
2) Patients who are pregnant or breast feeding
3) Patients who have received SGLT2 inhibitors within 4 weeks
4) Patients who have received hemodialysis within 4 weeks
5) Patients who are treated for peritonitis within 4 weeks
6) Patients with a daily urine volume of less than 500 mL
7) Patients who have difficulty with infusion and drainage of peritoneal dialysis dialysate
8) Patients who are considering discontinuation of peritoneal dialysis within 8 weeks after enrollment.
9) Patients who have difficulty performing bioelectrical impedance analysis tests (pacemakers, and limb defects)
10) Patients who are allergic to dapagliflozin
11) Patients who are considered inappropriate to participate by investigators

Study & Design

• Study Type: Interventional
• Study Design: Not specified